Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.

British journal of cancer - 22 Aug 2017

Winther-Larsen Anne, Demuth Christina, Fledelius Joan, Madsen Anne Tranberg, Hjorthaug Karin, Meldgaard Peter, Sorensen Boe Sandahl

Abstract excerpt

BACKGROUND: Mutated circulating cell-free DNA (cfDNA) has been suggested as a surrogate marker of tumour burden and aggressiveness of disease. We examined the association between the level of plasma mutant cfDNA and metabolic tumour burden (MTB) measured by 18F-fluoro-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT). Furthermore, the presence of mutant cfDNA was correlated with patient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Fluorodeoxyglucose F18

Share to Glycolysis

Share to Positron Emission Tomography Computed Tomography

Share to Radiopharmaceuticals

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 28683468
DOI: 10.1038/bjc.2017.215
PMCID: PMC5572172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.PMID 28683468Read ↗

Associations between tumor mutations in cfDNA and survival in non-small cell lung cancer.Semantic proximity Read ↗

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer.Semantic proximity Read ↗

Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.Semantic proximity Read ↗

Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Prospective clinical evaluation of cell-free DNA next generation sequencing in patients with suspected metastatic lung cancer.Semantic proximity Read ↗

Circulating Tumor DNA Analysis in Blood for the Prediction of Treatment Response in Patientswith Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.Semantic proximity Read ↗

The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.Semantic proximity Read ↗

Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC.Semantic proximity Read ↗

Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer.Semantic proximity Read ↗

Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Semantic proximity Read ↗

Assessment of the Mutational Status of NSCLC Using Hypermetabolic Circulating Tumor CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.